sameAs
Small-molecule-induced Rho-inhibition: NSAIDs after spinal cord injuryA p38 substrate-specific MK2-EGFP translocation assay for identification and validation of new p38 inhibitors in living cells: a comprising alternative for acquisition of cellular p38 inhibition dataInferential NMR/X-ray-based structure determination of a dibenzo[a,d]cycloheptenone inhibitor-p38α MAP kinase complex in solutionMetabolically stable dibenzo[b,e]oxepin-11(6H)-ones as highly selective p38 MAP kinase inhibitors: optimizing anti-cytokine activity in human whole bloodTargeting the Gatekeeper MET146 of C-Jun N-Terminal Kinase 3 Induces a Bivalent Halogen/Chalcogen BondWhy Antidiabetic Vanadium Complexes are Not in the Pipeline of "Big Pharma" Drug Research? A Critical ReviewAntithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX inhibitory activityThe effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosaPGE(2) in the regulation of programmed erythrocyte deathDiscovery of novel orally active anti-inflammatory N-phenylpyrazolyl-N-glycinyl-hydrazone derivatives that inhibit TNF-α productionDeoxyhypusine hydroxylase from Plasmodium vivax, the neglected human malaria parasite: molecular cloning, expression and specific inhibition by the 5-LOX inhibitor zileutonTofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors: design, synthesis, and biological data of inhibitors with improved physicochemical properties.One-pot synthesis of 4,6-diaryl-2-oxo(imino)-1,2-dihydropyridine-3-carbonitrile; a New Scaffold for p38alpha MAP kinase inhibition.Modeling and benchmark data set for the inhibition of c-Jun N-terminal kinase-3.Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord.Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore?Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept.Entada africana fraction CH₂Cl₂/MEOH 5% inhibits inducible nitric oxide synthase and pro-inflammatory cytokines gene expression induced by lipopolysaccharide in microgliaA new in vitro model to study cellular responses after thermomechanical damage in monolayer cultures.Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres.In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition.Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritisOsteoarthritis therapy--are there still unmet needs?Small molecular anti-cytokine agents.Are vanadium compounds drugable? Structures and effects of antidiabetic vanadium compounds: a critical review.New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase.SCISSOR-Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol.Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selection.Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.Successful structure-based design of recent p38 MAP kinase inhibitors.p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011).p38 MAPK inhibitors: a patent review (2012 - 2013).Inhibitors of c-Jun N-terminal kinases: an update.Sesquiterpene lactones as inhibitors of IL-8 expression in HeLa cells.c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.
P50
Q27025964-42AD4B5C-6323-40EE-94FA-F2BA2E7C6006Q27335745-566E8CC7-06BB-4A9D-B88B-AFC4D26A1489Q27676868-8510AC9C-E606-41EC-9EE2-F033FA911465Q27687230-855302C2-B3A7-4E1F-BFA3-0F33747DBF52Q27702526-FABB5116-3D17-4FCE-8759-10976E7D24EEQ28068342-8C4EE1B4-6B81-4A54-916A-97BB30BB520CQ28192983-A093572E-7781-4D25-928B-E2EC76463B3EQ28194351-E58A6966-4383-447D-9030-3A9315D77A3CQ28218548-8FD089A9-D67C-477A-AC46-06BD2B65D98BQ28484258-2BBB97A9-29B8-413C-B227-9DF46D3901B2Q28487727-2E68C1E9-2DBD-4F5C-BCDB-DF4801D28CA5Q30313903-3B4B9FF7-871A-4CE6-8B34-DBB4DD9CE6F3Q33413956-FEFE1B10-BA94-43B2-8491-B0A54BE09730Q33592490-6DFA7B6F-CD9D-4522-AC64-CCF7CA224D50Q33807396-3DB1D7B5-E782-45BA-A273-7D020B9D7741Q33885584-144258EC-45EF-4B66-8A31-4536269907C1Q34060626-FC684DC1-A979-4F81-9345-63EB090EDCCCQ34275256-193043F9-D9AE-4E48-B2F0-61144F193AB6Q35007084-F73EB446-78D2-4241-B2F6-4538788C311EQ35070411-43A0965B-D90E-4C43-A144-C960E54F3794Q35228409-3F898ED1-2588-456B-89B8-6002DF96EFA8Q35250612-69D7A2EC-6D02-4069-9BC6-BB8C7EE9D9EDQ35432166-8DF25DE6-652A-40A8-BC0B-896F8E26850DQ35491481-1641120B-2A7C-4C21-A889-91DFC7C8CE1AQ35553179-A46D6BBC-C975-4F9B-91BE-3600B1F765EAQ35643105-7355F2B5-0763-4F24-A5AF-7AB038876B50Q36311663-37671C11-2B80-4BDE-BE5A-D21D98AC541AQ36322184-449CA5EF-D41B-4354-B53A-CF100B3245F8Q36384990-9A7AEC57-8F94-4BE1-A55E-D34634C40A43Q37133751-A1D65CBE-AC41-45D9-B673-BA9632BD8C68Q37187664-F37DFEF4-3033-46A2-A2D8-62C4C3912032Q37222698-05C15316-FDAB-4922-88AD-F08E9864FF43Q37581860-BB7A87A1-8F2C-4D42-8D17-B38CA2FD9FDBQ37955936-2CC53DC3-0364-4EDB-A6DB-0FE62F464878Q38194600-A8F139A9-D108-40CE-B815-6BF618941952Q38270314-B87D2F2F-3CEA-4E03-946E-9371EEECBE6FQ38318133-17515AD6-40D1-425D-B72E-CA6C37020BCAQ38492604-061820E8-CF92-47D2-B74A-BB580D8F2E42Q38506135-EA91A333-D5CD-497A-B240-4725836998D3Q38606755-D3B72F2E-0630-41F9-A6B9-C2F54BB156CC
P50
description
German pharmacist
@en
cógaiseoir Gearmánach
@ga
deutscher Apotheker und Profes ...... ard Karls Universität Tübingen
@de
farmacéutico alemán
@es
pharmacist German
@en-ca
pharmacist German
@en-gb
صيدلي ألماني
@ar
name
Stefan Laufer
@ast
Stefan Laufer
@ca
Stefan Laufer
@de
Stefan Laufer
@en
Stefan Laufer
@es
Stefan Laufer
@fr
Stefan Laufer
@nl
Stefan Laufer
@sl
type
label
Stefan Laufer
@ast
Stefan Laufer
@ca
Stefan Laufer
@de
Stefan Laufer
@en
Stefan Laufer
@es
Stefan Laufer
@fr
Stefan Laufer
@nl
Stefan Laufer
@sl
prefLabel
Stefan Laufer
@ast
Stefan Laufer
@ca
Stefan Laufer
@de
Stefan Laufer
@en
Stefan Laufer
@es
Stefan Laufer
@fr
Stefan Laufer
@nl
Stefan Laufer
@sl
P214
P227
P244
P106
P21
P213
0000 0001 1876 5392
P214
P227
P244
n2003130085
P31
P496
0000-0001-6952-1486
P569
1959-12-16T00:00:00Z
P735
P7859
lccn-n2003130085